Sale to Genpact
Our attorneys have advised the shareholders of client Pharmalink Consulting, a leading global provider of regulatory affairs consulting services to the life sciences industry, on the sale of the company to business processes and operations provider Genpact Ltd (NYSE: G).
As a consequence of the acquisition, Genpact will add significant consulting, outsourcing and operations capabilities and will expand its capabilities in supporting life sciences research and development functions, including regulatory strategy, filing submissions, complex compliance services and the management of post-licensing activities. On completion of the transaction, which is subject to a few customary conditions, Pharmalink’s employees based in the US, UK, India, Ireland and Puerto Rico will become part of Genpact’s Life Sciences vertical market. The consideration for the sale remains confidential.
"It has been a privilege to advise on this transaction, which will prove extremely timely in the wider context of the life sciences industry," said Sean Scanlon, the lead partner on the transaction. "The combination of Pharmalink Consulting’s top-tier regulatory affairs consulting offerings and Genpact’s added scale, technology and other significant strengths will prove to be a very compelling proposition."
"This transaction represents a pivotal moment in the development of our business and Sean and the legal team have provided expert advice and guidance throughout the process” said Peter Griffin, Chairman, Pharmalink Consulting."